{"entity":{"id":"fujirebio","kind":"company","name":"Fujirebio","aka":["Fujirebio Diagnostics","H.U. Group"],"tldr":"The Japanese immunoassay company, part of H.U. Group, whose Malvern, Pennsylvania laboratory holds the original CA 19-9 and CA-125 tumour marker assays and licenses the antibodies to the big analyser makers.","summary":"Fujirebio is a Tokyo-based in vitro diagnostics company within H.U. Group Holdings. Its United States subsidiary, Fujirebio Diagnostics in Malvern, Pennsylvania, descends from Centocor Diagnostics, where the CA 19-9 and CA-125 immunoassays were developed in the early 1980s, and it still supplies the reference antibodies and assays (CA 19-9, CA-125 II, HE4, CYFRA 21-1, ProGRP) that run on its own Lumipulse analysers and, under licence, on the platforms of other manufacturers. The company is also a major supplier of Alzheimer's disease biomarker tests, and its oncology business centres on ovarian, pancreatic and lung cancer markers.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.fujirebio.com"}],"tags":[],"related":[],"cancers":["ovarian","pancreatic","nsclc"],"sections":[],"technologies":["serum-tumour-markers","proteomics-platforms"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo, Japan","country":"JP","companyType":"diagnostics","website":"https://www.fujirebio.com","investors":[],"funding":[]},"route":"/companies/fujirebio/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"proteomics-platforms","kind":"technology","name":"Proteomics instruments and affinity platforms","route":"/technologies/proteomics-platforms/"},{"id":"serum-tumour-markers","kind":"technology","name":"Serum tumour markers: proper use and misuse","route":"/technologies/serum-tumour-markers/"}]}}